**Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas**

David Kryza¹ ² *, Frédéric Debordeaux³ ⁴, Laurent Azéma⁵ ⁶ ⁷, Aref Hassan⁵ ⁶ ⁷, Olivier Paurelle⁵ ⁶ ⁷, Jürgen Schulz³ ⁴, Catherine Savona-Baron³, Elsa Charignon², Pauline Bonazza², Jacqueline Taleb¹, Philippe Fernandez³ ⁴, Marc Janier¹ ² ‡, Jean Jacques Toulmé⁵ ⁶ ⁷ ‡

¹ UNIV Lyon, Université Claude Bernard Lyon 1, LAGEP UMR 5007 CNRS, Villeurbanne, France, ² Hospices Civils de Lyon, Imthernat plateform, Lyon, France, ³ Université de Bordeaux, CNRS, INCIA, UMR 5287, Bordeaux, France, ⁴ Service de Médecine Nucléaire, CHU de Bordeaux, Bordeaux, France, ⁵ Inserm U1212, Bordeaux, France, ⁶ CNRS UMR5320, Pessac, France, ⁷ University of Bordeaux, ARNA Laboratory, Bordeaux, France

‡ MJ and JJT are co-directors of this work.

* david.kryza@chu-lyon.fr

**Abstract**

The human Matrix MetalloProtease-9 (hMMP-9) is overexpressed in tumors where it promotes the release of cancer cells thus contributing to tumor metastasis. We raised aptamers against hMMP-9, which constitutes a validated marker of malignant tumors, in order to design probes for imaging tumors in human beings. A chemically modified RNA aptamer (F3B), fully resistant to nucleases was previously described. This compound was subsequently used for the preparation of F3B-Cy5, F3B-S-acetylmercaptoacetyltriglycine (MAG) and F3B-DOTA. The binding properties of these derivatives were determined by surface plasmon resonance and electrophoretic mobility shift assay. Optical fluorescence imaging confirmed the binding to hMMP-9 in A375 melanoma bearing mice. Quantitative biodistribution studies were performed at 30 min, 1h and 2 h post injection of ⁹⁹ᵐTc-MAG-aptamer and ¹¹¹In-DOTA-F3B. ⁹⁹ᵐTc radiolabeled aptamer specifically detected hMMP-9 in A375 melanoma tumors but accumulation in digestive tract was very high. Following i.v. injection of ¹¹¹In-DOTA-F3B, high level of radioactivity was observed in kidneys and bladder but digestive tract uptake was very limited. Tumor uptake was significantly (student t test, p<0.05) higher for ¹¹¹In-DOTA-F3B with 2.0%ID/g than for the ¹¹¹In-DOTA-control oligonucleotide (0.7%ID/g) with tumor to muscle ratio of 4.0. Such difference in tumor accumulation has been confirmed by ex vivo scintigraphic images performed at 1h post injection and by autoradiography, which revealed the overexpression of hMMP-9 in sections of human melanomas. These results demonstrate that F3B aptamer is of interest for detecting hMMP-9 in melanoma tumor.
Introduction

Among oncological physiopathologic processes, angiogenesis appears to be a promising way for targeted therapies [1]. In this process, matrix metalloproteinases (MMP) are one of main actors of degradation of the extracellular matrix and basement membrane, facilitating tumor cell invasion [2]. Among them, MMP-9 is over-expressed in numerous malignant tumors [3] and particularly in cutaneous malignant melanoma [4–5].

Malignant melanoma is a tumor that arises from melanocytic cells and primarily involves the skin but it can also arise in the eye, meninges and on various mucosal surfaces. It can metastasize either by the lymphatic or haematogenous way. Distant metastases have a poor prognosis with no long-term curative treatment [6] and with a median survival in untreated patients being only 6–9 months. Efficient and accurate diagnosis is highly needed for this pathology. In high-risk patients, computerized tomography with or without FDG-positron emission tomography (FDG-PET) and magnetic resonance imaging may be indicated depending on the clinical findings. Nevertheless, those techniques lack specificity with relatively high false-positive rate and a low sensitivity for the detection of occult regional nodal metastases. Molecular imaging techniques, using specific target marker, are needed for in vivo mapping and measuring pathological processes at cellular or even molecular levels.

Developed in the early 1990s [7–9], aptamers are three-dimensional oligonucleotides, either with a deoxy- (DNA) or a ribo-scaffold (RNA). They bind with high affinity and high specificity to a large variety of targets ranging from small organic molecules to viruses and live cells [10–12], by interaction optimized by shape complementarity. Aptamers are generated by an iterative process of in vitro selection and amplification called SELEX (Systematic Evolution of Ligands by EXponential enrichment) [13] and can be chemically-modified thus generating powerful tools for biomedical applications [14]. Particular interest is being paid to aptamers obtained by cell-SELEX, recognizing membrane proteins and receptors [15–17]. A number of reports describe aptamers specific of tumor markers [18–19]. Such aptamers are used for many different purposes such as biosensing [20], delivery [21–22], flow-cytometry [23], diagnostics [24–25] and therapeutics [21, 26]. The binding characteristics of aptamers, namely high affinity and specific recognition of the target as well as their easy of synthesis made them excellent candidates for imaging. Aptamer-based probes have been engineered for monitoring several tumor markers: nucleolin [27], tenascin [28], PSMA [29], PTK7 or MUC1 glycoprotein [30–31], annexin A2 [32] or MMP-9 [33]. The versatility of oligonucleotide synthesis allows the chemical modifications od aptamers at defined positions without effect on their binding properties. Indeed different imaging modalities were implemented with aptamer probes: Magnetic Resonance Imaging (MRI) [34], optical imaging [30; 35] or nuclear imaging probe [36–37]. Promising results are available notably for the in vivo detection in animal models of tenascin [28], nucleolin [27] or MUC1 glycoprotein [31].

The F3B aptamer that we previously raised against the human MMP-9 exhibits the desired properties for an imaging agent: affinity in the low nanomolar range, high specificity of binding and full nuclease resistance due to a chemically modified backbone [33]. We previously demonstrated its interest for ex vivo imaging sections of human brain without any further in vivo evaluation. In the present study, we evaluated the ex vivo and in vivo melanoma tumor targeting efficiency of F3B towards hMMP-9 protein using a fluorescent or isotope labelled aptamer.

Materials and Methods

Oligonucleotide Synthesis

F3B and the control sequence, bearing a 5' hexylamino function, were synthesized on a 1 μmol scale with an ABI Expedite 8909 synthesizer, using conventional β-cyanoethyl phosphoramidite
chemistry (2′OMe-purine and 2′F-pyrimidine). Once purified (electrophoresis on denaturing gels: 20% (19:1 acrylamide/bis-acrylamide), 7M urea, Tris-Borate-EDTA buffer), oligonucleotides were conjugated to DOTA or Cy5, according to a previously described protocol for MAG3 coupling [33]. Briefly, 20 nmol of oligonucleotide were suspended in 100 μL of binding buffer (sodium bicarbonate/sodium carbonate 0.25 M, pH 8.3, sodium chloride 1 M, sodium ethylenediaminetetraacetate 1 mM) and gently stirred at room temperature. DOTA-NHS (Chematech®) or Cy5-NHS (Interchim®) (3 mg, in 30 μL of DMF) was added in portions at room temperature over 3 h. After complete addition, the suspension was stirred for an additional hour, and the crude was directly purified by HPLC (Macherey-Nagel Nucleodur column, 0.1 M triethylammonium acetate, pH 7.0, (acetonitrile/0.1 M triethylammonium acetate, pH 7.0: 80/20) gradient) to afford the oligonucleotide conjugates in 50–90% yield. Conjugate characterization was performed through MALDI-ToF mass spectrometry (Reflex III, Bruker) or Electrospray ionization (LCT Premier, Waters).

Protein

The human MMP-9 was purchased from Calbiochem; samples were checked for purity by SDS polyacrylamide gel electrophoresis.

Specificity Assays

**Surface Plasmon Resonance.** The specificity of F3B-DOTA and F3B-Cy5 derivatives for hMMP-9 was determined through competition with the F3B unmodified aptamer monitored by surface plasmon resonance (BiaCore 3000 apparatus, BiaCore AB, Sweden). 5′-biotin F3B and its control were immobilized on a Xantec™ SAD 200m chip (50 μL of 50 nM solution in PBS buffer, at a rate of 20 μL/min). HMMP9 was firstly injected at 20 μL/min on F3B and control channel. Then hMMP-9 (50 nM in PBS buffer) was incubated with F3B or with the control labelled derivatives (200 nM in PBS buffer) and injected on F3B-immobilized channel (80 μL, 20 μL/min) at 23°C. The complexes were dissociated with a pulse of a solution containing 40% formamide/3.6 M urea/30 mM EDTA.

**Electrophoretic Mobility Shift Assay.** MMP9/F3B-Cy5 complex was visualized on acrylamide/bis-acrylamide 37.5/1 8% native gel. The polymerization and electrophoresis buffer was TBE 0.5X (Euromed). F3B-Cy5 (20nM) and MMP9 (100nM) were allowed to form the complex at room temperature. Increasing concentration of competitor (0-100nM) was then added and the samples were loaded onto the gel after 30 minutes of incubation. Electrophoresis was performed on a cooled support (4°C) at 150 V. The fluorescence measurement was performed on an Imagequant (LAS4000, GE) at 635 nm for excitation and 670 nm for emission. Intensity of the shift band was calculated with ImageJ software.

Oligonucleotide sequences

2′OMe-R; 2′F-Y; X = hexylamino phosphate; Y = hexaethyleneglycol phosphate

F3Bomf-NH₂, 5′ -XY UGC CCU GCC CUC ACC CGU UAG CCU GAG CGC CCC GCA-3′

Control-NH₂, 5′ -XY UGC CAA ACG CGU CCC CUU UGC CCG GCC UCC GCC GCA-3′

Oligonucleotides Radiolabelling

**Technetium 99m labelling.** F3B-MAG3-aptamer and MAG3-control-sequence were labelled by modifying an existing protocol. Briefly, the oligonucleotides (20 μg) were dissolved in phosphate buffer saline (PBS, 20 μL) in a sterile vial. Then 20 μL of a mixture of sodium tartrate (50 mg/mL) in sterile 0.5 M sodium bicarbonate, 0.18 M ammonium hydroxide, 0.25 M...
ammonium acetate were added to the vial following by immediately adding 2 μL of a freshly prepared SnCl₂·2H₂O solution in HCl 0.1 N (1 mg/mL). ²⁹⁹ᵐTcO₄⁻ was eluted as a physiological saline solution from a commercial ⁹⁹ᵐMo/⁹⁹ᵐTc generator obtained from Cisbio-international (Saclay, France). ⁷⁴ MBq of ⁹⁹ᵐTcO₄⁻ was then added to the mixture, which was incubated 20 min at room temperature. The radiolabeling mixture was then purified from radiochemical impurities by steric exclusion chromatography through a PD-10 column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) as follows. The column was first washed with 15 mL of isotonic saline and the mixture solution was then loaded on the column followed by elution with isotonic saline. The radiochemical purity (RCP) was assayed with a gamma isotope TLC analyzer (Raytest, Courbevoie, France) using ITLC-SG (Biodex Tec-control black, Biodex, NY, USA) and methyletylcetone (MEK) as mobile phase. Finally, the fractions with the highest radiochemical purities were pooled.

**Indium ¹¹¹ labelling.** F3B-DOTA-aptamer and DOTA-control-sequence (20 μg) were labelled by adding 300 μL of acetate buffer 0.1 M pH5 and 30–70 MBq of high purity ¹¹¹In-chloride at room temperature for 45 min. Free indium ¹¹¹ was removed using a PD-10 column. The column was first washed with 15 mL of acetate buffer 0.1 M, then the labelled mixture was loaded on the column and eluted using acetate buffer. ¹¹¹In-DOTA-F3B or ¹¹¹In-DOTA-control were first eluted. RCP of each 0.5 mL fraction was evaluated using ITLC-SG (biodex, Tec-control black) and citrate buffer 50 mM (pH 5) as mobile phase. ¹¹¹In-DOTA-F3B or control remained at the origin whereas unbound indium ¹¹¹ migrated with an RF of 0.9–1. The highest radiochemical purity fractions were pooled.

**Stability testing.** For stability testing, an aliquot of the purified ⁹⁹ᵐTc-MAG3-F3B, ¹¹¹In-DOTA-F3B and labelled control-aptamer were incubated at 37°C in 2 mL phosphate buffer saline (pH 7.4) and radiochemical purity was evaluated as described above.

**Biodistribution studies**

Biodistribution studies were performed in compliance with the French guidelines and Ethics approval was obtained from the local animal committee of University Claude Bernard Lyon 1. Mice were obtained from Janvier labs (Saint-Berthevin, France). All animals were housed under standard environmental conditions at ambient temperature of 25°C and cared with free access to water and food. For all experiments, mice were anaesthetized using a gaseous protocol (isoflurane / oxygen (2.5%/2.5%)). Melanoma bearing mice were obtained by subcutaneous injection of 3.10⁵ cells of human malignant melanoma A375 in the right flank or in the paw of nude mice (6–8 weeks old, 20-25g).

**Quantitative biodistribution studies.** 1 to 10 MBq of radiolabeled aptamer in a maximum volume of 100 μL were intravenously injected into mice bearing human melanoma tumors (n = 3 or 4 for each groups). Mice were sacrificed at defined time points: 30 min, 2 and 4 h after injection by cervical dislocation. Tissues of interest (blood, heart, lungs, spleen, kidneys, muscles, brain, and skin) were removed, weighted and radioactivity was counted for 5 min in a gamma scintillation counter (Wizard⁴⁰ gamma counter, Perkin Elmer, USA). Urine and feces were collected thanks to individual metabolic cage for housing animals and counts. Tissue distribution was expressed as the percentage of injected dose per gram (%ID/g). Renal and hepatobiliary elimination were expressed as cumulated radioactivity under total injected activity. Tumor to muscle ratio (TMR) was calculated using the following formula: (%ID/g tumor) / (%ID/g muscle).

**Blood half-life of radiolabeled aptamer.** After i.v. injection of 1–2 MBq of radiolabeled aptamer, blood samples were removed at different time intervals: 2 min, 5 min, 10 min, 15 min, 30 min and 1 hour and were weighted and counted for 5 min in a gamma counter. Data points were fitted to an exponential decay function.
Imaging protocol

**Ex vivo** planar scintigraphic imaging was performed on posterior paw being removed and positioned over the collimator of a dedicated small animal Nano-SPECT-CT system (BIOSCAN™, Washington DC, USA) at 1 hour after i.v. injection of radiolabeled $^{111}$In-aptamer. The acquisition was performed during 10 minutes with two 15% windows centered on the two peaks 171 keV and 245 keV of indium 111.

**In vivo and ex vivo fluorescence imaging.** Optical imaging was performed thanks to a back-thinned CCD-cooled camera (ORCAIIBT-512G, Hamamatsu phonics, Massy, France) using a colored glass long-pass RG 665 filter (Melles Griot, Voisins les Bretonneaux, France), which cuts off all excitation light. Dorsal images were acquired 1h after i.v. injection of 100 μL of Cy5-F3B-aptamer or Cy5-control-sequence (1 to 5 nmol) into mice bearing human melanoma tumors. Mice were sacrificed at 1h post injection and tissues of interest (kidneys, liver, brain, spleen, heart, lungs bone, skin muscle, digestive tract and tumor) were imaged.

**Immunohistochemical analysis.** Patients samples used in these studies were obtained after written informed consent in accordance with the Declaration of Helsinki and stored at the "CRB Cancer des Hôpitaux de Toulouse" collection. According to the French law, CRB Cancer collection has been declared to the Ministry of Higher Education and Research (DC-2008-463) and a transfer agreement (AC-2008-820) was obtained after approbation by ethical committees ("Cancéropole Grand Sud Ouest"). Clinical and biological annotations of the samples have been declared to the CNIL (Comité National Informatique et Libertés).

Different types of well-characterized tumors were formalin-fixed and paraffin-embedded (Single Spread Melanoma, Nodular Melanoma, Acral lentiginous melanoma, Lentigo Malignant Melanoma (Dubreuilh’s melanoma), nodes/metastases). Immunohistochemical hMMP-9 detection was performed on serial sections in order to validate radiolabeling analysis, using a purified anti-hMMP-9 mouse monoclonal antibody (ab58803, Abcam). Appropriate positive and negative controls omitting the primary antibody have been included with every slide run.

Representative paraffin embedded 5 μm thick sections were dewaxed with xylene, rehydrated through a graded alcohol series, and washed with distilled water. A blocking step is needed in order to block endogenous peroxidase activity. Moreover, antigen-unmasking procedure was applied to achieve optimum staining.

After washing with TBS, the slides were saturated, and then incubated with the hMMP-9 antibody (ab58803, 1:300) overnight in humidified atmosphere at room temperature. Sections were washed twice with TBS tween 1%, and ImmPRESS peroxidase Reagent kit (rabbit anti-mouse antibody, ImmPRESS™, Vector) was then applied as the secondary antibody in moist chamber for 30 min. Tissue sections were stained with AEC (3-Amino-9-EthylCarbazole, ab 64252, Abcam, Cambridge) for 15 min and counterstained with hematoxylin for examination. Immunoreactivity was evaluated in the cell cytoplasm, cytoplasmic membrane, and in the extracellular matrix.

**Radiolabeling of tumor tissue sections.** As for immunohistochemical analysis, binding studies were performed using tumor sections, but incubated in the presence of either $^{111}$In-DOTA-F3B aptamer or $^{111}$In-DOTA-control sequence. 5 μm thick slices were deparaffinised and prepared as previously described.

These slices were incubated with $^{111}$In-DOTA-F3B aptamer and adjacent section with $^{111}$In-DOTA-control-sequence for 60 min at room temperature (15 kBq/40 μL). Unfixed radioligand was removed with PBS-Tween 0.05% and slices were washed in distilled water. Radioactivity was finally evaluated using a micro-imager 2000 (Biospace Mesures, Paris, France).
Results

Characteristics of hMMP-9 aptamer and specificity assays

The solid phase synthesis of oligonucleotides allows the controlled incorporation of appending group anywhere into the aptamer sequence through phosphoramidite chemistry. We opted for the 5' modification of aptamer, with the display of a reactive amino group, used for conjugation with N-hydroxysuccinimide ester activated labels. This amine function is away from the oligonucleotide part through the incorporation during synthesis of various spacers: a dimer of 2’deoxy-thymidine or a hexaethyleneglycol group. The first spacer was used in the case of cyanine-5 incorporation, whereas the second spacer was used for DOTA ligation. Beside biodistribution modulation problems, we had to firstly confirm that 5’ appending groups are not disrupting the F3B-MMP-9 complex formation efficiency. For this purpose, we settled a competition assay, monitored by surface plasmon resonance and electrophoretic mobility shift assay. Results are reported on Fig 1. A biotinylated F3B variant was loaded on the streptavidin sensor chip. This variant was able to detect its target at a usual KD of 10 nM. The pre-incubation of the protein (50 nM) with F3B labelled either with cyanine-5 or DOTA group (200 nM) led to the abolition of complex formation on sensor chip. This result was not observed when the control oligonucleotide was used for pre-incubation. It confirms that variants, F3B-Cy5 and F3B-DOTA, preserve three-dimensional features of the aptamer and that the appending groups don’t interfere with the recognition region. As a second control, an electrophoretic mobility shift assay was performed. It clearly demonstrates the specificity of the aptamer, as F3B was able to displace the F3B-Cy5-MMP9 complex whereas the competition with the control did not abolish the complex formation.

Radiolabelling and stability

After steric exclusion chromatography purification, radiolabeled aptamer were obtained with radiochemical purity (RCP) exceeding 98% and 96% for technetium 99m and indium 111 respectively. Radiochemical yields were 70% for 99mTc-MAG-aptamer and 15–20% for 111In-DOTA-aptamer. For both radionuclides at 4 hours after incubation at 37°C in phosphate buffer saline pH 7.4, RCP purity was still greater than 95% indicating a suitable kinetic stability to perform in vitro and in vivo experiments.

Biodistribution of 99mTc-MAG-F3B and 99mTc-MAG-control

Biodistribution studies were performed in A375 melanoma bearing mice at 30 min, 1 h and 2 h post injection of radiolabeled oligonucleotides and are presented in Fig 2. After i.v. injection of 99mTc-aptamer, high level of radioactivity were observed in kidneys and bladder with more than 48.0 ± 8.8% ID and 60.6 ± 7.7% ID eliminated through renal excretion for 99mTc-MAG-F3B and 99mTc-MAG-control, respectively. High levels of radioactivity were also observed in digestive tract and liver with value of 7.7 ± 1.6% ID/g and 13.5 ± 1.6% ID/g at 30 min post injection and 24.4 ± 8.0%ID/g and 5.7 ± 2.7%ID/g at 2h post injection for 99mTc-MAG-F3B compared to 7.5 ± 3.6%ID/g and 12.5 ± 1.7%ID/g at 30 min post injection and 18.5 ± 3.0%ID/g and 6.0 ± 0.8%ID/g at 2 h post injection for 99mTc-MAG-control indicating also an hepatobiliary clearance of the 99mTc-aptamers. No significant accumulation in other organs was observed for both 99mTc-oligonucleotides at any time. The highest tumor uptake was observed at 1h post injection for the aptamer derivatives with values of 1.8 ± 1.2%ID/g which was significantly higher (Student t test, P < 0.05) than for the control ones (0.15 ± 0.03%ID/g). The tumor to muscle ratio (TMR) value for 99mTc-MAG-F3B was 7.6 at 1h post injection respectively compared to 4.4 for the 99mTc-MAG-control.
Biodistribution of $^{111}$In-DOTA-F3B and $^{111}$In-DOTA-control

In order to evaluate the influence of the chelator on the aptamer biodistribution and the tumor targeting, biodistribution studies were performed at 30 min, 1 h and 2 h post injection of $^{111}$In-DOTA-F3B and $^{111}$In-DOTA-control. The results are presented in Fig 3. Both aptamers were rapidly cleared from the blood pool (average blood half-life: 11 min) and demonstrated low uptake in normal organs and tissues except from kidneys and liver. The uptake of radiolabeled DOTA aptamers in the digest tract was very low, with value of 0.9 ± 0.6%ID/g and 0.7 ± 0.1% ID/g at 30 min and 1 h post injection, respectively for $^{111}$In-DOTA-F3B and 0.6 ± 0.2%ID/g and 0.6 ± 0.2%ID/g for $^{111}$In-DOTA-control at 30 min and 1 h post injection, respectively. Tumor uptake was significantly (student t test, p<0.05) higher for $^{111}$In-DOTA-F3B with values of 2.0 ± 1.1% ID/g at 1 h post injection than for the $^{111}$In-DOTA-control (0.7 ± 0.2%ID/g). TMR were 4.0 at 1 h post injection for $^{111}$In-DOTA-F3B and 0.3 for $^{111}$In-DOTA-control, respectively.
Fig 2. Quantitative biodistribution of $^{99m}$Tc-MAG-aptamer and $^{99m}$Tc-MAG-control aptamer as function of post i.v. injection delay expressed as % of injected dose per gram of tissue.

doi:10.1371/journal.pone.0149387.g002
Imaging studies

*In vivo* fluorescent images acquired 1 h after i.v. injection of Cy5-F3B or Cy5-control-sequence into mice bearing human melanoma tumors are presented in Fig 4. Fluorescence staining allowed visualizing the kidneys and the liver and identifying the tumor with Cy5-F3B. Fluorescence imaging of the dissected organs and tumor tissues acquired 1 h after i.v. injection of Cy5-F3B-aptamer revealed well the highest fluorescent organs (i.e.: liver and kidneys) and revealed a moderate signal in the tumor. Such difference in tumor accumulation between F3B and its control has been confirmed by *ex vivo* scintigraphic images performed at 1 h post injection (Fig 5).

Immunohistochemistry and autoradiography

MMP-9 expression was first investigated in several human tumors from skin by immunohistochemistry using a specific hMMP-9 antibody. Healthy skin was used as MMP-9 negative control. The antibody was able to target active hMMP-9 (83 kDa) and pro-hMMP-9 (92 kDa). Immunohistochemical study revealed that hMMP-9 was overexpressed in melanomas. Strong reactivity was mainly observed in the cytoplasm of numerous tumor cells (Fig 6E). Immunopositivity was also present in the endothelial cells of blood vessels in the tumor environment and
disturbing background was also observed in epidermis and in sebaceous glands (Fig 6D). As shown in Fig 6, the hMMP-9 expression, monitored by immunohistochemical analysis, showed an important staining in metastasis nodes whereas no immunoreactivity was detected either in conjunctive tissue or in healthy lymphocytes.

For the others primary tumors explored (superficial spread melanoma (pT1b), lentiginous malignant melanoma (pT1a), nodular melanoma (pT4b,N3M1), nodes/metastases), hMMP-9 immunostaining showed a variable but positive expression and the observation was easier in case of infiltrative tumors. The labelling of the adjacent slices of melanoma using $^{111}$In-DOTA-F3B or control aptamer tended to confirm the results previously obtained in
immunostaining. Micro-imager analysis showed a fair agreement with the interaction of the h-MMP-9 monoclonal antibody. The radiolabeled $^{111}$In-DOTA-F3B aptamer induced a strong signal compared to $^{111}$In-DOTA-control (Fig 7). One can notice that the difference was weaker for low-grade melanomas. Moreover, in accordance with immunohistochemical analysis, the highest signal was obtained with nodes/metastases. The merger of the obtained images revealed a good colocalization on this sample of nodular melanoma between the binding of the anti-

Fig 6. Immunostaining using anti-hMMP-9 murine monoclonal antibody. The antibody ab58803 localizing area of high expression of the integrin in respectively (A) Superficial Spread Melanoma, (B) Metastatic nodes, (C) Lentigo Malignant Melanoma. (D) Background in the immunohistochemical analysis of Superficial Spread Melanoma with staining of epidermis, endothelial cells and sebaceous glands. Immunohistochemical detection of hMMP-9 using ab58803 antibody in a mostly metastatic node, with specific cytoplasmic immunoreactivity in tumor cells (E) and negative results for conjunctive tissue and normal lymphocytes (F).

doi:10.1371/journal.pone.0149387.g006
hMMP-9 antibody and the labeling of the tracer (Fig 8). So binding intensities seemed to well correlate with the amount of hMMP-9 detected by immunohistochemistry.

Discussion

In the field of diagnostic imaging, aptamers have shown great promise as recognition units for tumor targeting [27; 29; 37]. Due to the advantage of their structure and properties (i.e. small size, non-immunogenic, similar binding affinity than antibodies), aptamers binds to their targets with high affinity and specificity. Up to date, limited studies have been performed for in vivo tumor targeting using an aptamer labelled with a SPECT radionuclide. In a previous study, our group has demonstrated that radiolabeled F3B aptamer was able to target in vitro
hMMP-9 protein, a tumor biomarker over-expressed in numerous various malignant tumor. In this study, we go a step further trying to evaluate ex vivo and in vivo melanoma tumor targeting using fluorescent or isotope labelled specific aptamer directed against hMMP-9 protein.

Due to the instability of small oligonucleotides in biological fluids, a specific aptamer has been truncated down to 36 nucleotides by substitution of RNA residues by 2′-O-methyl derivatives to increase Rnase/nuclease resistance in order to be able to perform in vivo studies.

First of all, F3B-DOTA and F3B-Cy5 affinity to hMMP-9 were evaluated using surface plasmon resonance experiments. Functionalized aptamer remained able to bind to hMMP-9 and its pro-form with a strong avidity since competition experiments performed with unmodified aptamer F3B immobilized on the chip in the presence of F3B-DOTA or F3B-Cy5 conjugates with MMP-9 lead to abolish the SPR signal. When optical tagged, the intra-venous injection of Cy5-F3B-aptamer in mice bearing melanoma increased fluorescence signal inside the tumor. This demonstrates an active targeting to hMMP-9 since Cy5-control-sequence did not allow us to localize the tumor. However, since penetration of near infrared light in tissues is limited to a few centimeters [38] with low spatial resolution [39] and limited ability to perform in vivo quantitative biodistribution, precise biodistribution of specific aptamer directed against hMMP9 and control aptamer was performed thanks to the immobilization of technetium 99m
inside a chelate (MAG3). The use of technetium 99m isotope for radiolabeling aptamer has several advantage including a suitable half-life, appropriate gamma photon energy, availability and low cost. In this study, we efficiently labelled $^{99m}$Tc-MAG3-aptamer with high radiochemical purity and yield. MAG3 chelator is of particular interest as a bifunctional technetium chelator because it allows forming stable $^{99m}$TcO core efficiently and rapidly and reduces serum proteins binding [40]. Due to their small size, blood clearance of both aptamers was very fast with a rapid diffusion leading to a maximal tumor uptake of 1.8%ID/g at 1h with a tumor to blood ratio of 9 for $^{99m}$Tc-MAG-F3B-aptamer. Nevertheless, accumulation and retention in digestive tract at different time points of both $^{99m}$Tc-MAG3-aptamer were very high (more than 18%ID/g), as frequently observed in previous reports [37; 41]. This important uptake was probably due to the lipophilicity of the radiolabeled compounds [42]. In such context, the detection of melanoma tumor and their metastases would be particularly difficult in the digestive and abdominal region leading us to envisage the use of a more hydrophilic and anionic chelate (i.e. DOTA) which is able to complex a wide variety of imaging or therapeutic radiometals including indium 111 which could label DOTA at high radiochemical purity in mild condition. In contrast to $^{99m}$Tc-MAG3-aptamer, the use of DOTA chelator conjugates to the aptamer decrease dramatically the digestive tract uptake (< 2% ID/g at any time points) for $^{111}$In-DOTA-F3B aptamer and $^{111}$In-DOTA-control-aptamer. The biodistribution study of $^{111}$In-DOTA-F3B revealed a slightly tumor uptake at 30 min and 1h post injection compared to the $^{99m}$Tc-MAG-F3B-aptamer. These results support previous works confirming that various chelators could significantly affect the in vitro and in vivo biodistribution of the radiolabeled target.

The highest A375 human melanoma tumor uptake of $^{111}$In-DOTA-F3B aptamer compared to the $^{111}$In-DOTA-control-sequence was confirmed ex vivo by autoradiography and by scintigraphic images. Nevertheless, even if human tumor cell lines transplants in athymic mice are widely used for evaluating the targeting efficiency of a potential probe, the murine xenograft model has some limitations for representing the physiopathology and many aspects of human real cancer. In such context, ex vivo imaging of human slice of various grade of melanoma tissues have been performed using $^{111}$In-DOTA-aptamer and compared to hMMP-9 expression by immunostaining. This is an important step to obtain a preliminary indication of the relevant use of indium 111 labelled hMMP-9 aptamer on clinical neoplasms. First of all, our results confirmed the over expression of hMMP-9 in melanoma tumors and were well correlated with the binding intensities of $^{111}$In-F3B-DOTA even if the anti-hMMP-9 antibody used for immunostaining was raised against the mouse MMP-9 with lower specificity compared to the aptamer F3B. Moreover, hMMP-9 expression and $^{111}$In-F3B-DOTA binding corroborated to the grade of malignancy whereas the radiolabeled control sequence induced a weaker signal confirming the binding specificity of $^{111}$In-DOTA-F3B to its target. The presence of DOTA, which is known to be a strong chelator for a variety of beta- or alpha metals such as Lutetium 177, Yttrium 90 or Bismuth 213 allows us to envisage their use in radionuclide therapy. To reach this goal, we are currently investigating the use of a dendritic structure bearing 2 F3Bomf aptamer since our group has recently demonstrated [43] that multivalency on a single dendron structure could highly increase tumor targeting thanks to their cooperative effect [44].

**Acknowledgments**

This study—Imelapt—was supported by a public grant from the French Agence Nationale de la Recherche within the context of the Investments for the Future Program, referenced ANR-10-LABX-57 and named TRAIL.
Author Contributions
Conceived and designed the experiments: DK FD LA PF MJ JJT. Performed the experiments: DK FD LA AH OP CSB EC PB JT JS. Analyzed the data: DK FD LA AH OP JS CSB EC PB JT PF MJ JJT. Contributed reagents/materials/analysis tools: DK FD LA AH OP JS CSB EC PB JT. Wrote the paper: DK FD LA PF MJ JJT.

References
1. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS 2005; 2(3):e70.
2. Forget MA, Desrosiers RR, and Béliveau R. (1999). Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can. J. Physiol. Pharmacol. 2005, 77:465–480. PMID: 10535707
3. Merdad A, Karim S, Schulten HJ, Dallol A, Buhmeida A, Al-Thubaity F et al. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis. Anticancer Res. 2014; 34(3):1355–66. PMID: 24596383
4. Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol. 2000; 115(3):337–44. PMID: 10951266
5. Chen Y, Chen Y, Huang L, Yu J. Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma. Anticancer Res. 2014; 34(3):1355–66. PMID: 24596383
6. Finn L, Markovic SN, and Joseph RW. Therapy for metastatic melanoma: the past, present, and future. BMC Med. 2012; 10, 23. doi: 10.1186/1741-7015-10-23 PMID: 22385436
7. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacterio-phage T4 DNA polymerase. Science. 1990; 249(4968): 505–10. PMID: 2200121
8. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990; 346(6287): 818–22. PMID: 1697402
9. Robertson DL, Joyce GF. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature. 1990; 344(6265):467–8. PMID: 1690861
10. Nimjee SM, Rusconi CP and Sullenger BA. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 2005; 56:555–583. PMID: 15660527
11. Bunka D.H; Stockley PG. Aptamer Come of Age—at last. Nat.Rev. Microbiol. 2006; 4: 558–596.
12. Lee SJ, Kwon YS, Lee J-e, Choi EJ, Lee CH, Song JY et al. Detection of vr-2332 strain of porcine reproductive and respiratory syndrome virus type ii using an aptamer-based sandwich-type assay. Anal Chem. 2012; 85: 66–74. doi: 10.1021/ac3026866 PMID: 23198789
13. Stoltenburg R, Reinemann C, Strehlitz B. SELEX—a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng. 2007; (4: ):381–403. PMID: 17627883
14. Shigdar S, Macdonald J, O’Connor M, Wang T, Xiang D, Al Shamali H et al. Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors(Basel). 2013; 13(10):13624–37.
15. Pestourie C, Tavitian B, and Duconge F. Aptamers against extracellular targets for in vivo applications. Biochimie 2005; 87:921–930. PMID: 15963620
16. Wang J, and Li G. Aptamers against cell surface receptors: selection, modification and application. Curr. Med. Chem 2011; 18:4107–4116. PMID: 21838694
17. Tan W, Donovan MJ, and Jiang J. Aptamers from Cell-Based Selection for Bioanalytical Applications. Chem Rev. 2013; 113(4): 2842–62. doi: 10.1021/cr300468v PMID: 23509854
18. Xiang D, Shigdar S, Qiao G, Wang T, Kouzani AZ, Zhou SF et al. Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics. 2015; 5(1): 23–42. doi: 10.7150/thno.10202 PMID: 25553096
19. Lao YH, Phua KKL, and Leong KW. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS Nano. 2015; 9(3): 2235–54. doi: 10.1021/nn507494p PMID: 25731717
20. Sun H and Zu Y. Aptamers and their applications in nanomedicine. Small. 2015; 11(20):2352–64. doi: 10.1002/smll.201403073 PMID: 25677591
21. Dassie JP and Giangrande P.H. Current progress on aptamer-targeted oligonucleotide therapeutics. Ther Deliv. 2013; 4(12):1527–46. doi: 10.4155/tde.13.118 PMID: 24304250
22. Kruspe S, Mittelberger F, Szameit K, Szameit K, and Hahn U. Aptamers as drug delivery vehicles. ChemMedChem 2014; 9: 1998–2011. doi: 10.1002/cmdc.201402163 PMID: 25130604
23. Meyer M, Scheper T, and Walter JG. Aptamers: versatile probes for flow cytometry. Appl. Microbiol. Biotecnol. 2013; 97:7097–7109. doi: 10.1007/s00253-013-5070-z PMID: 23838792
24. Shum KT, Zhou J, and Rossi JJ. Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. J Cancer Ther. 2013; 4(4):872–890. PMID: 25057429
25. Ozalp VC, Kavruk M, Dilek O, and Bayrac AT. Aptamers: molecular tools for medical diagnosis. Curr Top Med Chem. 2015; 15(12):1125–37. PMID: 25866272
26. Zhu G, Ye M, Donovan MJ, Song E, Zhao Z, Tan W. Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem Commun (Camb). 2012; 48(85):10472–80.
27. Noaparast Z, Hosseinimehr SJ, Piramoon M, Abedi SM. Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells. J Drug Target. 2015; 12:1–9.
28. Jacobson O, Yan X, Niu G, Ma Y, Szajek LP, Shen B, Kiesewetter DO et al. PET Imaging of Tenascin-C with a Radiolabeled Single-Stranded DNA Aptamer. J Nucl Med. 2015; 56(4):616–21. doi: 10.2967/jnumed.114.149484 PMID: 25698784
29. Javier DJ, Nitin N, Levy M, Ellington A, and Richards-Kortum R. Aptamer-Targeted Gold Nanoparticles with Unexpected Identification from Cell-SELEX of an Anti-Annexin A2 aptamer targeting tumors. PLoS One. 2014; 9(1):e87002. doi: 10.1371/journal.pone.0087002 PMID: 24898926
30. Zhang C, Ji X, Zhang Y, Zhou G, Ke X, Wang H et al. One-pot synthesized aptamer-functionalized CdTe:ZnS quantum dots for tumor-targeted fluorescence imaging in vitro and in vivo. Anal Chem. 2013; 85(12):5843–9. doi: 10.1021/ac4006066 PMID: 23682757
31. Chen H, Zhao J, Zhang M, Yang H, Ma Y, Gu Y. MUC1 aptamer-based near-infrared fluorescence probes for tumor imaging. Mol Imaging Biol. 2015; 17(1):38–49. doi: 10.1007/s11307-014-0763-y PMID: 25050106
32. Cibiel A, Quang NN, Gombert K, Thézé B, Garofalakis A, Ducongé F. From ugly duckling to swan: unexpected identification from cell-SELEX of an anti-Annexin A2 aptamer targeting tumors. PLoS One. 2014; 9(1):e87002. doi: 10.1371/journal.pone.0087002 PMID: 24898926
33. Da Rocha Gomes S, Miguel J, Eimer S, Ries C, Dausse E et al. (99m)Tc-MAG3-aptamer for imaging of melanomas targeting by F3B Aptamer. J Cancer Ther. 2013; 4(4):689–94. doi: 10.1007/s12112-013-0763-y
34. Yu MK, Kim D, Lee I-H, et So J-S, Jeong YY, Jon S et al. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small. 2011; 7:2241–9. doi: 10.1002/smll.201100472 PMID: 21648076
35. Shi H, Tang Z, Kim Y, Nie H, Huang YF, He X et al. In vivo fluorescence imaging of tumors using molecular aptamers generated by cell-selex. Chem-Asian J. 2010; 5:2209–13.
36. Tavitian B, Ducongé F, Boisgard R, Dolié F. In vivo imaging of oligonucleotidic aptamers. Methods Mol Biol. 2008; 535:241–59. doi: 10.1007/978-1-59745-557-2_15 PMID: 19377991
37. Hicke BJ, Stephens AW, Gould T, Chang Y-F, Lynott CK, Heil J et al. Tumor targeting by an aptamer. Mol Imaging Biol. 2015; 17(1):38
38. Winnard P, Chang F, Rusckowski M, et al. Preparation and use of NHS-MAG3 for technetium-99m methotrexate conjugates as tumor imaging agents. Cancer Biother Radiopharm. 2006 Feb; 21 (1):49–60. PMID: 16480331
39. Smith AM, and Nie S. Next-generation quantum dots. Nat. Biotechnol. 2009; 27:732–733. doi: 10.1038/nbt0809-732 PMID: 19668181
40. Winnard P, Chang F, Rusckowski M, et al. Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. Nucl. Med. Biol. 1997; 24:425–32. PMID: 9290078
41. Shi J, Kim YS, Chakraborty S, Jia B, Wang F, Liu S. 2-Mercaptocetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics. Bioconjug Chem. 2009 Aug 19; 20(8):1559–68. doi: 10.1021/bc9001739 PMID: 19603780
42. Okarvi SM, Jammaz IA. Preparation and in vitro and in vivo evaluation of technetium-99m-labeled folate and methotrexate conjugates as tumor imaging agents. Cancer Biother Radiopharm. 2006 Feb; 21 (1):49–60. PMID: 16480331
43. Parat A, Kryza D, Degoul F, Taleb J, Villard C, Janier M et al. Radiolabeled dendritic probes as tools for high in vivo tumor targeting: application to melanoma. J. Mater. Chem. B 2015; 3:2560–2571.
44. Rolland O, Turrisi CO, Caminade AM, and Majoral JP. Dendrimers and nanomedicine: multivalency in action. New J. Chem. 2009; 33:1809–1824.